{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:31:36Z","timestamp":1761129096980},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T00:00:00Z","timestamp":1383696000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T00:00:00Z","timestamp":1383696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Gouty arthritis (gout) is primarily cared for in ambulatory care settings. Although the prevalence of gout in the US is thought to be increasing, there have been few data on this as well as temporal changes in gout medication use.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We analyzed annual visit and drug utilization data from national sample surveys of physician practices and hospital outpatient clinics in the US from 1993 to 2009. Gout diagnosis was recorded by individual physicians.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Result<\/jats:title>\n                        <jats:p>The frequency of visits for gout increased three-fold from 1993 through 2009; most of the increases were observed from 2003 onwards. The increase was only partly explained by changes in age and gender composition of the surveys over time. A concomitant increase in prescriptions for allopurinol and colchicine and decrease in prescriptions for anti-inflammatories was observed. Aspirin use, a putative risk factor for gout and gout flares, increased substantially over this period. Probenecid use was negligible. Frequency of systemic steroid use has not changed over time.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>The number of ambulatory visits for gout has increased almost three-fold in the first decade of the millennium coinciding with increases in physician and patient awareness. This increase was primarily due to visits among the elderly. Uricosuric use remained negligible whereas the uses of allopurinol and colchicine have increased rapidly. Use of traditional non-steroidals has declined, possibly due to safety concerns whereas glucocorticoid use remains unchanged.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4370","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T02:06:31Z","timestamp":1383703591000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Trends in physician diagnosed gout and gout therapies in the US: results from the national ambulatory health care surveys 1993 to 2009"],"prefix":"10.1186","volume":"15","author":[{"given":"Eswar","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,6]]},"reference":[{"key":"4041_CR1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/ard.2007.076232","volume":"67","author":"L Annemans","year":"2008","unstructured":"Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005. Ann Rheum Dis. 2008, 67: 960-966. 10.1136\/ard.2007.076232.","journal-title":"Ann Rheum Dis"},{"key":"4041_CR2","first-page":"1582","volume":"31","author":"KL Wallace","year":"2004","unstructured":"Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R: Increasing prevalence of gout and hyperuricemia over 10\u00a0years among older adults in a managed care population. J Rheumatol. 2004, 31: 1582-1587.","journal-title":"J Rheumatol"},{"key":"4041_CR3","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/rheumatology\/ken305","volume":"47","author":"HK Choi","year":"2008","unstructured":"Choi HK, De Vera MA, Krishnan E: Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology. 2008, 47: 1567-1570. 10.1093\/rheumatology\/ken305.","journal-title":"Rheumatology"},{"key":"4041_CR4","doi-asserted-by":"publisher","first-page":"R10","DOI":"10.1186\/ar3684","volume":"14","author":"E Krishnan","year":"2012","unstructured":"Krishnan E, Pandya BJ, Lingala B, Hariri A, Dabbous O: Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther. 2012, 14: R10-10.1186\/ar3684.","journal-title":"Arthritis Res Ther"},{"key":"4041_CR5","first-page":"164","volume":"14","author":"EQ Wu","year":"2008","unstructured":"Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E: Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008, 14: 164-175.","journal-title":"J Manag Care Pharm"},{"key":"4041_CR6","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/ard.2007.081604","volume":"67","author":"JA Singh","year":"2008","unstructured":"Singh JA, Strand V: Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008, 67: 1310-1316.","journal-title":"Ann Rheum Dis"},{"key":"4041_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/rheumatology\/kep047","volume":"48","author":"SJ Lee","year":"2009","unstructured":"Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A: Perceptions of disease and health-related quality of life among patients with gout. Rheumatology. 2009, 48: 582-586.","journal-title":"Rheumatology"},{"key":"4041_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"P Khanna","year":"2012","unstructured":"Khanna P, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri JT, Khanna D: Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health and quality of life outcomes. 2012, 10: 117-10.1186\/1477-7525-10-117.","journal-title":"Health and quality of life outcomes"},{"key":"4041_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.semarthrit.2010.07.001","volume":"40","author":"JA Singh","year":"2011","unstructured":"Singh JA, Sarkin A, Shieh M, Khanna D, Terkeltaub R, Lee SJ, Kavanaugh A, Hirsch JD: Health care utilization in patients with gout. Semin Arthritis Rheu. 2011, 40: 501-511. 10.1016\/j.semarthrit.2010.07.001.","journal-title":"Semin Arthritis Rheu"},{"key":"4041_CR10","first-page":"498","volume":"35","author":"E Krishnan","year":"2008","unstructured":"Krishnan E, Lienesch D, Kwoh CK: Gout in ambulatory care settings in the United States. J Rheumatol. 2008, 35: 498-501.","journal-title":"J Rheumatol"},{"key":"4041_CR11","unstructured":"Centers for Disease Control and Prevention. [http:\/\/www.cdc.gov\/nchs\/ahcd.htm]"},{"key":"4041_CR12","unstructured":"Cerner Multum. [http:\/\/www.multum.com\/]"},{"key":"4041_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10654-011-9563-8","volume":"26","author":"MJ Knol","year":"2011","unstructured":"Knol MJ, Pestman WR, Grobbee DE: The (mis)use of overlap of confidence intervals to assess effect modification. Eur J Epidemiol. 2011, 26: 253-254. 10.1007\/s10654-011-9563-8.","journal-title":"Eur J Epidemiol"},{"key":"4041_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V","volume":"41","author":"RC Lawrence","year":"1998","unstructured":"Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998, 41: 778-799. 10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V.","journal-title":"Arthritis Rheum"},{"key":"4041_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1126\/science.2649979","volume":"244","author":"GB Elion","year":"1989","unstructured":"Elion GB: The purine path to chemotherapy. Science. 1989, 244: 41-47. 10.1126\/science.2649979.","journal-title":"Science"},{"key":"4041_CR16","unstructured":"Gout Awareness: Gout Awareness. [http:\/\/conversionplanet.com\/case-studies-2\/gout-awareness\/]"},{"key":"4041_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0196859908329090","volume":"33","author":"TN Dubriwny","year":"2009","unstructured":"Dubriwny TN: Constructing breast cancer in the news: Betty Ford and the evolution of the breast cancer patient. J Comm Inq. 2009, 33: 104-125.","journal-title":"J Comm Inq"},{"key":"4041_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/ard.2004.024091","volume":"64","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Saag KG: Gout epidemiology: results from the UK General Practice Research Database, 1990\u20131999. Ann Rheum Dis. 2005, 64: 267-272. 10.1136\/ard.2004.024091.","journal-title":"Ann Rheum Dis"},{"key":"4041_CR19","first-page":"1143","volume":"231","author":"GP Rodnan","year":"1975","unstructured":"Rodnan GP, Robin JA, Tolchin SF, Elion GB: Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA. 1975, 231: 1143-1147.","journal-title":"Efficacy of a single daily dose. JAMA"},{"key":"4041_CR20","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3899\/jrheum.080487","volume":"36","author":"EQ Wu","year":"2009","unstructured":"Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E: Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?. J Rheumatol. 2009, 36: 1032-1040. 10.3899\/jrheum.080487.","journal-title":"J Rheumatol"},{"key":"4041_CR21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18553\/jmcp.2008.14.2.164","volume":"14","author":"EQ Wu","year":"2008","unstructured":"Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E: Disease-related and all-cause health care costs of elderly patients with gout. J Managed Care Pharm. 2008, 14: 164-175.","journal-title":"J Managed Care Pharm"},{"key":"4041_CR22","first-page":"908","volume":"22","author":"MB Ferraz","year":"1995","unstructured":"Ferraz MB, O'Brien B: A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995, 22: 908-914.","journal-title":"J Rheumatol"},{"key":"4041_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/acr.21837","volume":"65","author":"R Garg","year":"2012","unstructured":"Garg R, Sayles HR, Yu F, Michaud K, Singh J, Saag KG, Mikuls TR: Gout-related healthcare utilization in U.S. emergency departments, 2006 through 2008. Arthrit Care Res. 2012, 65: 571-577.","journal-title":"Arthrit Care Res"},{"key":"4041_CR24","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","volume":"44","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB: Fernandes S, Saag KG: Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford). 2005, 44: 1038-1042. 10.1093\/rheumatology\/keh679.","journal-title":"Rheumatology (Oxford)"},{"key":"4041_CR25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/art.20102","volume":"50","author":"TR Mikuls","year":"2004","unstructured":"Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, Bilker WB, Saag KG: Quality of care indicators for gout management. Arthritis Rheum. 2004, 50: 937-943. 10.1002\/art.20102.","journal-title":"Arthritis Rheum"},{"key":"4041_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11926-996-0046-y","volume":"7","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Saag KG: Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?. Curr Rheumatol Rep. 2005, 7: 242-249. 10.1007\/s11926-996-0046-y.","journal-title":"Curr Rheumatol Rep"},{"key":"4041_CR27","doi-asserted-by":"publisher","first-page":"d7459","DOI":"10.1136\/bmj.d7459","volume":"343","author":"W Lipworth","year":"2011","unstructured":"Lipworth W, Kerridge I, Brett J, Day R: How clinical and research failures lead to suboptimal prescribing: the example of chronic gout. BMJ. 2011, 343: d7459-10.1136\/bmj.d7459.","journal-title":"BMJ"},{"key":"4041_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrd3748","volume":"11","author":"J Kotz","year":"2012","unstructured":"Kotz J: The gout pipeline crystallizes. Nat Rev Drug Discov. 2012, 11: 425-426. 10.1038\/nrd3748.","journal-title":"Nat Rev Drug Discov"},{"key":"4041_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR: Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009, 68: 51-56.","journal-title":"Ann Rheum Dis"},{"key":"4041_CR30","first-page":"S398","volume":"63","author":"J Sundy","year":"2011","unstructured":"Sundy J, Perez-Ruiz F, Krishnan E, Hingorani V, Welp J, Suster M, Manhard K, Cravets M, Hagerty D, Quart B: Efficacy and safety of Lesinurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: preliminary results from the randomized, double-blind, placebo-controlled, Phase 2B extension study. Arthritis Rheum. 2011, 63: S398-S399.","journal-title":"Arthritis Rheum"},{"key":"4041_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.50.9.631","volume":"50","author":"T Yamamoto","year":"1991","unstructured":"Yamamoto T, Moriwaki Y, Takahashi S, Suda M, Higashino K: Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis. 1991, 50: 631-633. 10.1136\/ard.50.9.631.","journal-title":"Ann Rheum Dis"},{"key":"4041_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3899\/jrheum.101160","volume":"38","author":"SL Stocker","year":"2011","unstructured":"Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO: Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol. 2011, 38: 904-910. 10.3899\/jrheum.101160.","journal-title":"J Rheumatol"},{"key":"4041_CR33","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/rheumatology\/ker286","volume":"50","author":"KW Moon","year":"2011","unstructured":"Moon KW, Kim J, Kim JH, Song R, Lee EY, Song YW, Lee EB: Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia. Rheumatology. 2011, 50: 2278-2282. 10.1093\/rheumatology\/ker286.","journal-title":"Rheumatology"},{"key":"4041_CR34","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/rheumatology\/kel353","volume":"45","author":"R Madhok","year":"2006","unstructured":"Madhok R, Wu O, McKellar G, Singh G: Non-steroidal anti-inflammatory drugs\u2013changes in prescribing may be warranted. Rheumatology. 2006, 45: 1458-1460. 10.1093\/rheumatology\/kel353.","journal-title":"Rheumatology"},{"key":"4041_CR35","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1185\/03007990903017966","volume":"25","author":"R Halpern","year":"2009","unstructured":"Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR: Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009, 25: 1711-1719. 10.1185\/03007990903017966.","journal-title":"Curr Med Res Opin"},{"key":"4041_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C, Pillinger MH: Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011, 124: 155-163. 10.1016\/j.amjmed.2010.09.012.","journal-title":"Am J Med"},{"key":"4041_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/11592750-000000000-00000","volume":"28","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, Jordan S: The challenges of gout management in the elderly. Drugs & aging. 2011, 28: 591-603. 10.2165\/11592750-000000000-00000.","journal-title":"Drugs & aging"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4370\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:05:17Z","timestamp":1728381917000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,6]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,12]]}},"alternative-id":["4041"],"URL":"https:\/\/doi.org\/10.1186\/ar4370","relation":{},"ISSN":["1478-6354"],"issn-type":[{"type":"electronic","value":"1478-6354"}],"subject":[],"published":{"date-parts":[[2013,11,6]]},"assertion":[{"value":"8 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R181"}}